SION Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
34.8M
+7.2%
32.5M
+9.7%
29.6M
+25.4%
23.6M
-0.5%
23.7M
R&D
22.0M
+0.7%
21.9M
+15.3%
19.0M
+25.0%
15.2M
-5.5%
16.0M
SG&A
12.8M
+20.6%
10.6M
-0.3%
10.6M
+26.0%
8.4M
+8.8%
7.8M
Operating Income
-34825000
-7.2%
-32473000
-9.7%
-29599000
-25.4%
-23612000
+0.5%
-23734000
EBITDA
-34671000
-7.3%
-32318000
-9.8%
-29445000
-25.5%
-23460000
+0.4%
-23545000
Net Income
-32418000
-8.5%
-29886000
-11.6%
-26779000
-31.0%
-20440000
-0.8%
-20278000
EPS (Basic)
$-0.72
-9.1%
$-0.66
-10.0%
$-0.60
-30.4%
$-0.46
+0.0%
$-0.46
EPS (Diluted)
$-0.72
-9.1%
$-0.66
-10.0%
$-0.60
-30.4%
$-0.46
+0.0%
$-0.46
Shares (Diluted)
45.2M
+0.1%
45.1M
+0.5%
44.9M
+0.1%
44.9M
+1.4%
44.3M
Sionna Therapeutics (SION) — Financials